Alan Naylor

3.2k citations

72 papers · 2.2k · h-index 25

Impact in

Pharmacology top 1%
- Cannabis and Cannabinoid Research
Physiology top 2%
- Alzheimer's disease research and treatments

Papers in

Organic Chemistry 37
- Asymmetric Synthesis and Catalysis 16
- Synthesis and Biological Evaluation 11
- Chemical synthesis and alkaloids 5
Pharmacology 24
- Inflammatory mediators and NSAID effects 20

Co-authors: Iain P. Chessell (13 shared papers)Praveen Anand (4 shared papers)P. Facer (2 shared papers)C. Bountra (2 shared papers)Pascal F. Durrenberger (2 shared papers)Stephen G. Davies (13 shared papers)Y. Yiangou (1 shared paper)David Middlemiss (9 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (18 papers)Tetrahedron Letters (6 papers)Journal of Medicinal Chemistry (4 papers)Journal of the Chemical Society Perkin Transactions 1 (4 papers)British Journal of Pharmacology (3 papers)
Partner nations: United Kingdom United States Australia

In The Last Decade

Alan Naylor

72 papers receiving 2.1k citations

Peers

Countries citing papers authored by Alan Naylor

Since Specialization

Citations

This map shows the geographic impact of Alan Naylor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Naylor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Naylor more than expected).

Fields of papers citing papers by Alan Naylor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Naylor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Naylor. The network helps show where Alan Naylor may publish in the future.

Co-authors

The 25 scholars most cited alongside Alan Naylor, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alan Naylor Line = papers co-authored together Alan Naylor links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 72 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord BMC Neurology ·Y. Yiangou, P. Facer, Pascal F. Durrenberger, Iain P. Chessell, Alan Naylor, C. Bountra, Richard R Banati, Praveen Anand	2006	447
2	Oral administration of a potent and selective non‐peptidic BACE‐1 inhibitor decreases β‐cleavage of amyloid precursor protein and amyloid‐β production in vivo Journal of Neurochemistry ·Ishrut Hussain, Julie A. Hawkins, David C. Harrison, Christopher J. Hille, Gareth Wayne, Leanne Cutler, Tania Buck, Daryl S. Walter, Emmanuel H. Demont, Colin Howes, Alan Naylor, Philip Jeffrey, María Isabel González, Colin Dingwall, Anton D. Michel, Sally Redshaw, John B. Davis	2006	143
3	Discovery of 2-[(2,4-Dichlorophenyl)amino]- N -[(tetrahydro- 2 H -pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain Journal of Medicinal Chemistry ·Gerard M.P. Giblin, Celestine T. O’Shaughnessy, Alan Naylor, William L. Mitchell, Andrew J. Eatherton, Brian P. Slingsby, D. Anthony Rawlings, Paul Goldsmith, Andrew J. Brown, Carl Haslam, Nick M. Clayton, Alex Wilson, Iain P. Chessell, Andrew R. Wittington, Richard Green	2007	112
4	Neuroprotective actions of GR89696, a highly potent and selective κ‐opioid receptor agonist British Journal of Pharmacology ·P.J. Birch, H. L. Rogers, Ann G. Hayes, Neil J. Hayward, M.B. Tyers, D. I. C. SCOPES, Alan Naylor, Duncan B. Judd	1991	84
5	A potent new class of .kappa.-receptor agonist: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)methyl]piperazines Journal of Medicinal Chemistry ·Alan Naylor, Duncan B. Judd, Jane E. Lloyd, D. I. C. SCOPES, Ann G. Hayes, Philip J. Birch	1993	83
6	A hyperspectral fluorescence lifetime probe for skin cancer diagnosis Review of Scientific Instruments ·Pieter De Beule, Christopher Dunsby, Neil P. Galletly, Gordon Stamp, A.C. Chu, Uma Anand, Praveen Anand, Christopher D. Benham, Alan Naylor, P. M. W. French	2007	80
7	Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: In vivo studies Journal of Controlled Release ·Faron Jordan, Alan Naylor, Catherine A. Kelly, Steven M. Howdle, Andrew L. Lewis, Lisbeth Illum	2009	74
8	Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy Bioorganic & Medicinal Chemistry Letters ·Adrian Hall, Andy Billinton, Susan H. Brown, Nicholas M. Clayton, A. R. Chowdhury, Gerard M.P. Giblin, Paul Goldsmith, Thomas G. Hayhow, David N. Hurst, Ian R. Kilford, Alan Naylor, Barry Passingham, Lisa Winyard	2008	69
9	Multifocal multiphoton excitation and time correlated single photon counting detection for 3-D fluorescence lifetime imaging Optics Express ·Sunil Kumar, Christopher Dunsby, Pieter De Beule, Dylan M. Owen, Uma Anand, Peter M. P. Lanigan, Richard K.P. Benninger, Daniel M. Davis, Mark A. A. Neil, Praveen Anand, Christopher D. Benham, Alan Naylor, P. M. W. French	2007	61
10	Discovery of 1-[4-(3-Chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a Brain Penetrant 5-Azaindole CB₂Agonist for the Treatment of Chronic Pain Journal of Medicinal Chemistry ·Gerard M.P. Giblin, Andrew Billinton, Michael A. Briggs, Andrew J. Brown, Iain P. Chessell, Nick M. Clayton, Andrew J. Eatherton, Paul Goldsmith, Carl Haslam, Matthew R. Johnson, William L. Mitchell, Alan Naylor, Alcide Perboni, Brian P. Slingsby, Alex Wilson	2009	47
11	Asymmetric synthesis of β-amino-γ-substituted-γ-butyrolactones: double diastereoselective conjugate addition of homochiral lithium amides to homochiral α,β-unsaturated esters Organic & Biomolecular Chemistry ·Thais Cailleau, Jason Cooke, Stephen G. Davies, Kenneth B. Ling, Alan Naylor, Rebecca L. Nicholson, Paul D. Price, Paul M. Roberts, Angela J. Russell, Andrew D. Smith, James E. Thomson	2007	44
12	Piperidine-derived γ-secretase modulators Bioorganic & Medicinal Chemistry Letters ·Adrian Hall, Richard L. Elliott, Gerard M.P. Giblin, Ishrut Hussain, James Musgrave, Alan Naylor, Rosemary Sasse, Beverley Smith	2009	42
13	The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain Bioorganic & Medicinal Chemistry Letters ·Gerard M.P. Giblin, Rino A. Bit, Susan H. Brown, Helene Chaignot, A. R. Chowdhury, Iain P. Chessell, Nicholas M. Clayton, Tanya Coleman, Adrian Hall, Beverley Hammond, David N. Hurst, Anton D. Michel, Alan Naylor, Riccardo Novelli, Tiziana Scoccitti, David J. Spalding, Sac Pham Tang, Alex Wilson, Rich Wilson	2006	42
14	Cyclooxygenase‐2 (Cox‐2) in injured human nerve and a rat model of nerve injury Journal of the Peripheral Nervous System ·Pascal F. Durrenberger, P. Facer, Roy Gray, Iain P. Chessell, Alan Naylor, C. Bountra, Richard B. Banati, Rolfe Birch, Praveen Anand	2004	41
15	Discovery of novel, non-acidic 1,5-biaryl pyrrole EP1 receptor antagonists Bioorganic & Medicinal Chemistry Letters ·Adrian Hall, Stephen J. Atkinson, Susan H. Brown, Iain P. Chessell, A. R. Chowdhury, Gerard M.P. Giblin, Paul Goldsmith, Mark P. Healy, Karamjit S. Jandu, Matthew R. Johnson, Anton D. Michel, Alan Naylor, Jennifer Sweeting	2006	41
16	A new method for stereoselective homoallylic amine synthesis Journal of the Chemical Society Perkin Transactions 1 ·Susan K. Armstrong, E. W. COLLINGTON, Julian G. Knight, Alan Naylor, Stuart Warren	1993	39
17	Characterization of the herpes simplex virus origin binding protein interaction with OriS. Journal of Biological Chemistry ·Daria J. Hazuda, Helen C. Perry, Alan Naylor, W.L. McClements	1991	38
18	GR94839, a κ‐opioid agonist with limited access to the central nervous system, has antinociceptive activity British Journal of Pharmacology ·H. L. Rogers, P.J. Birch, Susan M. Harrison, Emma Palmer, Gary R. Manchee, Duncan B. Judd, Alan Naylor, D. I. C. SCOPES, Ann G. Hayes	1992	37
19	A series of novel, highly potent and selective agonists for the κ‐opioid receptor British Journal of Pharmacology ·Ann G. Hayes, P.J. Birch, Neil J. Hayward, Michael J. Sheehan, H. L. Rogers, M.B. Tyers, Duncan B. Judd, D. I. C. SCOPES, Alan Naylor	1990	32
20	4-[(Alkylamino)methyl]furo[3,2-c]pyridines: A New Series of Selective .kappa.-Receptor Agonists Journal of Medicinal Chemistry ·Alan Naylor, Duncan B. Judd, D. I. C. SCOPES, Ann G. Hayes, (unknown)	1994	31

About Alan Naylor

Alan Naylor is a scholar working on Organic Chemistry, Pharmacology, Molecular Biology, Cellular and Molecular Neuroscience and Physiology, having authored 72 papers that have together received 2.2k indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (20 papers), Asymmetric Synthesis and Catalysis (16 papers), Neuropeptides and Animal Physiology (13 papers), Synthesis and Biological Evaluation (11 papers), Receptor Mechanisms and Signaling (8 papers), Pharmacological Receptor Mechanisms and Effects (8 papers), Chemical Synthesis and Analysis (6 papers) and Chemical synthesis and alkaloids (5 papers). The work is most often cited by research in Pharmacology (563 citations), Physiology (133 citations), Cellular and Molecular Neuroscience (493 citations), Organic Chemistry (741 citations) and Neurology (148 citations). Alan Naylor has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Iain P. Chessell, Praveen Anand, P. Facer, C. Bountra, Pascal F. Durrenberger, Stephen G. Davies, Y. Yiangou, David Middlemiss, D. I. C. SCOPES and Gerard M.P. Giblin. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Tetrahedron Letters, Journal of Medicinal Chemistry, Journal of the Chemical Society Perkin Transactions 1 and British Journal of Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Alan Naylor

Impact in

Papers in i

In The Last Decade

Alan Naylor

Peers

Countries citing papers authored by Alan Naylor

Fields of papers citing papers by Alan Naylor

All Works

About Alan Naylor

Explore authors with similar magnitude of impact

Papers in